CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma
Open Access
- 26 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (13), 2899-2911
- https://doi.org/10.1182/bloodadvances.2019001346
Abstract
Cancer cells commonly develop resistance to immunotherapy by loss of antigen expression. Combinatorial treatments that increase levels of the target antigen on the surface of cancer cells have the potential to restore efficacy to immunotherapy. Here, we use our CRISPR interference– and CRISPR activation–based functional genomics platform to systematically identify pathways controlling cell surface expression of the multiple myeloma immunotherapy antigen B-cell maturation antigen (BCMA). We discovered that pharmacologic inhibition of HDAC7 and the Sec61 complex increased cell surface BCMA, including in primary patient cells. Pharmacologic Sec61 inhibition enhanced the antimyeloma efficacy of a BCMA-targeted antibody-drug conjugate. A CRISPR interference chimeric antigen receptor T cells (CAR-T cells) coculture screen enabled us to identify both antigen-dependent and antigen-independent mechanisms controlling response of myeloma cells to BCMA-targeted CAR-T cells. Thus, our study shows the potential of CRISPR screens to uncover mechanisms controlling response of cancer cells to immunotherapy and to suggest potential combination therapies.Keywords
This publication has 45 references indexed in Scilit:
- An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gateeLife, 2014
- Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding groupNature Chemical Biology, 2013
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBlood, 2012
- Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic PropertiesCancer Research, 2009
- The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cellsBlood, 2008
- POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17Oncogene, 2007
- A substrate-specific inhibitor of protein translocation into the endoplasmic reticulumNature, 2005
- Java Treeview—extensible visualization of microarray dataBioinformatics, 2004
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell ProfilesCritical Reviews™ in Immunology, 1995